Condition
Diffuse Systemic Sclerosis
Total Trials
6
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
16.7%
1 terminated out of 6 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
5Total
P 1 (3)
P 2 (1)
P 3 (1)
Trial Status
Completed2
Not Yet Recruiting1
Recruiting1
Unknown1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT07439029Phase 1Not Yet Recruiting
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
NCT07000916Recruiting
Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
NCT04837131Phase 2Terminated
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
NCT01538719Phase 1Completed
IL1-TRAP, Rilonacept, in Systemic Sclerosis
NCT01284322Phase 1CompletedPrimary
Fresolimumab In Systemic Sclerosis
NCT01586663Phase 3UnknownPrimary
Serial Night Time Position Splint on Systemic Sclerosis
Showing all 6 trials